Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México-Reference-Cited by-同舟云学术

Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in México

Published:2020-12 Issue: Volume:419 Page:117204
ISSN:0022-510X
Container-title:Journal of the Neurological Sciences
language:en
Short-container-title:Journal of the Neurological Sciences

Author:

Casallas-Vanegas Adriana,Gomez-Figueroa Enrique,de Saráchaga Adib Jorge,Zabala-Angeles Indhira,García-Estrada Christian,Salado-Burbano Jorge C.,DiazGranados-Palacio María Clara,Corona-Vázquez Teresita,de Jesús Flores-Rivera José,Rivas-Alonso Verónica

Publisher

Elsevier BV

Subject

Clinical Neurology,Neurology

Reference35 articles.

1. Neuromyelitis spectrum disorders;Weinshenker;Mayo Clin. Proc.,2017

2. Neuromyelitis optica: an update;Matà;J. Neurol. Sci. [Internet],2011

3. Treatment of neuromyelitis optica: review and recommendations;Kimbrough;Mult. Scler. Relat. Disord. [Internet].,2012

4. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response;Stellmann;J. Neurol. Neurosurg. Psychiatry,2017

5. Neurodegeneration in multiple sclerosis and neuromyelitis optica;Kawachi;J. Neurol. Neurosurg. Psychiatry [Internet].,2017

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of rituximab treatment regime on time to relapse in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder;Multiple Sclerosis and Related Disorders;2024-05

2. Systematic Review of Treatment Options and Therapeutic Responses for Lesions of the Sella and Orbit: Evidence-Based Recommendations;World Neurosurgery;2023-05

3. Optic neuromyelitis in relation with juvenile idiopathic arthritis: A case report;Revista Colombiana de Reumatología (English Edition);2022-10

4. A meta-analysis on efficacy and safety of rituximab for neuromyelitis optica spectrum disorders;Medicine;2022-09-09

5. Optimal retreatment schedule of rituximab for neuromyelitis optica spectrum disorder: A systematic review;Multiple Sclerosis and Related Disorders;2022-07